Nrf2 is essential for the chemopreventive efficacy of oltipraz against urinary bladder carcinogenesis

Cancer Research

Volumn 64, Issue 18, 2004, Pages 6424-6431

  Iida, Katsuyuki ^a,b   Itoh, Ken ^b   Kumagai, Yoshito ^b   Oyasu, Ryoichi ^c   Hattori, Kazunori ^a   Kawai, Koji ^a   Shimazui, Toru ^a   Akaza, Hideyuki ^a   Yamamoto, Masayuki ^b  

^a UNIVERSITY OF TSUKUBA   (Japan)

^b UNIVERSITY OF TSUKUBA   (Japan)

^c NORTHWESTERN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GLUCURONOSYLTRANSFERASE; GLUCURONOSYLTRANSFERASE 1A; N BUTYL N (4 HYDROXYBUTYL)NITROSAMINE; N NITROSOBUTYL (3 CARBOXYPROPYL)AMINE; OLTIPRAZ; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR NRF2; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; BLADDER; BLADDER CARCINOGENESIS; CANCER INHIBITION; CANCER INVASION; CANCER PREVENTION; CANCER SUSCEPTIBILITY; CONTROLLED STUDY; DETOXIFICATION; DRUG EFFICACY; ENZYME INDUCTION; GENE EXPRESSION; GENE EXPRESSION REGULATION; GLUCURONIDATION; LIVER; MOUSE; NONHUMAN; PRIORITY JOURNAL;

ANIMALS; ANTICARCINOGENIC AGENTS; BUTYLHYDROXYBUTYLNITROSAMINE; CARCINOGENS; DNA-BINDING PROTEINS; ENZYME INDUCTION; FEMALE; GENE EXPRESSION; GENETIC PREDISPOSITION TO DISEASE; GLUCURONIDES; GLUCURONOSYLTRANSFERASE; MALE; METABOLIC DETOXICATION, DRUG; MICE; MICE, INBRED C57BL; MICE, INBRED ICR; MICE, KNOCKOUT; MICROSOMES, LIVER; NF-E2-RELATED FACTOR 2; PYRAZINES; TRANS-ACTIVATORS; URINARY BLADDER; URINARY BLADDER NEOPLASMS;

EID: 4644328941     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-04-1906     Document Type: Article

References (50)

1. Wai CY, Miller DS. Urinary bladder cancer. Clin Obstet Gynecol 2002;45:844-54.
2. Case RA, Hosker ME, McDonald DB, Pearson JT. Tumours of the urinary bladder in workmen engaged in the manufacture and use of certain dyestuff intermediates in the British chemical industry. Part I. The role of aniline, benzidine, α-naphthylamine, and β-naphthylamine. Br J Ind Med 1954;11:75-96.
3. Tricker AR, Mostafa MH, Spiegelhalder B, Preussmann R. Urinary excretion of nitrate, nitrite and N-nitroso compounds in schistosomiasis and bilharzia bladder cancer patients. Carcinogenesis 1989;10:547-52.
4. Mirvish SS. Role of N-nitroso compounds (NOC) and N-nitrosation in etiology of gastric, esophageal, nasopharyngeal and bladder cancer and contribution to cancer of known exposures to NOC. Cancer Lett 1995;93:17-48.
5. Druckrey H, Preussmann R, Ivankovic S, Schmahl D. Organotropic carcinogenic effects of 65 various N-nitroso-compounds on BD rats. Z Krebsforsch 1967;69:103-201.
6. IARC. N-Nitrosodi-n-butylamine. IARC Monogr Eval Carcinog Risk Chem Man 1978;17:51-75.
7. Okada M, Ishidate M. Metabolic fate of N-n-butyl-N-(4-hydroxybutyl)- nitrosamine and its analogues. Selective induction of urinary bladder tumours in the rat. Xenobiotica 1977;7:11-24.
8. Ito N, Hiasa Y, Tamai A, Okajima E, Kitamura H. Histogenesis of urinary bladder tumors induced by N-butyl-N-(4-hydroxybutyl)nitrosamine in rats. Gann 1969;60:401-10.
9. Brockmoller J, Cascorbi I, Kerb R, Roots I. Combined analysis of inherited polymorphisms in arylamine N-acetyltransferase 2, glutathione S-transferases M1 and T1, microsomal epoxide hydrolase, and cytochrome P450 enzymes as modulators of bladder cancer risk. Cancer Res 1996;56:3915-25.
10. Johns LE, Houlston RS. N-acetyl transferase-2 and bladder cancer risk: a meta-analysis. Environ Mol Mutagen 2000;36:221-7.
11. Johns LE, Houlston RS. Glutathione S-transferase II (GSTM1) status and bladder cancer risk: a meta-analysis. Mutagenesis 2000;15:399-404.
12. Park SJ, Zhao H, Spitz MR, Grossman HB, Wu X. An association between NQO1 genetic polymorphism and risk of bladder cancer. Mutat Res 2003;536:131-7.
13. Giuliani L, Gazzaniga P, Caporuscio F, Ciotti M, Frati L, Agliano AM. Can down-regulation of UDP-glucuronosyltransferases in the urinary bladder tissue impact the risk of chemical carcinogenesis? Int J Cancer 2001;91:141-3.
14. Hashimoto Y, Kitagawa HS. In vitro neoplastic transformation of epithelial cells of rat urinary bladder by nitrosamines. Nature 1974;252:497-99.
15. Airoldi L, Magagnotti C, Bonfanti M, Fanelli R. α-Oxidative metabolism of the bladder carcinogens N-nitrosobutyl(4-hydroxybutyl)amine and N-nitrosobutyl(3-carboxypropyl)amine within the rat isolated bladder. Carcinogenesis 1990;11:1437-40.
16. Airoldi L, Magagnotti C, Bonfanti M, et al. Detection of O6-butyl- and O6-(4-hydroxybutyl)guanine in urothelial and hepatic DNA of rats given the bladder carcinogen N-nitrosobutyl(4-hydroxybutyl)amine. Carcinogenesis 1994;15:2297-301.
17. Talalay P. Chemoprotection against cancer by induction of phase 2 enzymes. Biofactors 2000;12:5-11.
18. Talalay P, Dinkova-Kostova AT, Holtzclaw WD. Importance of phase 2 gene regulation in protection against electrophile and reactive oxygen toxicity and carcinogenesis. Adv Enzyme Regul 2003;43:121-34.
19. Benson AM, Batzinger RP, Ou SY, Bueding E, Cha YN, Talalay P. Elevation of hepatic glutathione S-transferase activities and protection against mutagenic metabolites of benzo(a)pyrene by dietary antioxidants. Cancer Res 1978;38:4486-95.
20. Ansher SS, Dolan P, Bueding E. Biochemical effects of dithiolethiones. Food Chem Toxicol 1986;24:405-15.
21. Zhang Y, Talalay P, Cho CG, Posner GH. A major inducer of anticarcinogenic protective enzymes from broccoli: isolation and elucidation of structure. Proc Natl Acad Sci USA 1992;89:2399-403.
22. Clapper ML. Chemopreventive activity of oltipraz. Pharmacol Ther 1998;78:17-27.
23. Kensler TW, Groopman JD, Sutter TR, Curphey TJ, Roebuck BD. Development of cancer chemopreventive agents: oltipraz as a paradigm. Chem Res Toxicol 1999;12:113-26.
24. Primiano T, Sutter TR, Kensler TW. Antioxidant-inducible genes. Adv Pharmacol 1997;38:293-328.
25. Friling RS, Bensimon S, Daniel V. Xenobiotic-inducible expression of murine glutathione S-transferase Ya subunit gene is controlled by an electrophile-responsive element. Proc Natl Acad Sci USA 1990;87:6258-62.
26. Rushmore TH, Morton MR, Pickett CB. The antioxidant responsive element. J Biol Chem 1991;266:11632-9.
27. Itoh K, Igarashi K, Hayashi N, Nishizawa M, Yamamoto M. Cloning and characterization of a novel erythroid cell-derived CNC family transcription factor heterodimerizing with the small maf family proteins. Mol Cell Biol 1995;15:4184-93.
28. Moi P, Chan K, Asunis I, Cao A, Kan YW. Isolation of NF-E2-related factor 2 (Nrf2), a NF-E2-like basic leucine zipper transcriptional activator that binds to the tandem NF-E2/AP1 repeat of the α-globin locus control region. Proc Natl Acad Sci USA 1994;91:9926-30.
29. Venugopal R, Jaiswal AK. Nrf1 and Nrf2 positively and c-Fos and Fra1 negatively regulate the human antioxidant response element-mediated expression of NAD(P)H: quinone oxidoreductasel gene. Proc Natl Acad Sci USA 1996;93:14960-5.
30. Itoh K, Chiba T, Takahashi S, et al. An Nrf2/small Maf heterodimer mediates the induction of phase II detoxifying enzyme genes through antioxidant response elements. Biochem Biophys Res Commun 1997;236:313-22.
31. Chan K, Lu R, Chang JC, Kan YW. NRF2, a member of the NFE2 family of transcription factors, is not essential for murine erythropoiesis, growth, and development. Proc Natl Acad Sci USA 1996;93:13943-8.
32. Ishii T, Itoh K, Takahashi S, et al. Transcription factor Nrf2 coordinately regulates a group of oxidative stress-inducible genes in macrophages. J Biol Chem 2000;275:16023-9.
33. Ramos-Gomez M, Kwak MK, Dolan PM, et al. Sensitivity to carcinogenesis is increased and chemoprotective efficacy of enzyme inducers is lost in nrf2 transcription factor-deficient mice. Proc Natl Acad Sci USA 2001;98:3410-5.
34. Ramos-Gomez M, Dolan PM, Itoh K, Yamamoto M, Kensler TW. Interactive effects of nrf2 genotype and oltipraz on benzo[a]pyrene-DNA adducts and tumor yield in mice. Carcinogenesis 2003;24:461-7.
35. Fahey JW, Haristoy X, Dolan PM, et al. Sulforaphane inhibits extracellular, intracellular, and antibiotic-resistant strains of Helicobacter pylori and prevents benzo[a]pyrene-induced stomach tumors. Proc Natl Acad Sci USA 2002;99:7610-5.
36. Chan K, Han XD, Kan YW. An important function of Nrf2 in combating oxidative stress: detoxification of acetaminophen. Proc Natl Acad Sci USA 2001;98:4611-6.
37. Enomoto A, Itoh K, Nagayoshi E, et al. High sensitivity of Nrf2 knockout mice to acetaminophen hepatotoxicity associated with decreased expression of ARE-regulated drug metabolizing enzymes and antioxidant genes. Toxicol Sci 2001;59:169-77.
38. Chan K, Kan YW. Nrf2 is essential for protection against acute pulmonary injury in mice. Proc Natl Acad Sci USA 1999;96:12731-6.
39. Cho HY, Jedlicka AE, Reddy SP, et al. Role of NRF2 in protection against hyperoxic lung injury in mice. Am J Respir Cell Mol Biol 2002;26:175-82.
40. Aoki Y, Sato H, Nishimura N, Takahashi S, Itoh K, Yamamoto M. Accelerated DNA adduct formation in the lung of the Nrf2 knockout mouse exposed to diesel exhaust. Toxicol Appl Pharmacol 2001;173:154-60.
41. Oyasu R, Iwasaki T, Matsumoto M, Hirao Y, Tabuchi Y. Induction of tumors in heterotopic bladder by topical application of N-methyl-N-nitrosourea and N-butyl-N-(3-carboxypropyl)nitrosamine. Cancer Res 1978;38:3019-25.
42. Zhang YY, Ludwikowski B, Hurst R, Frey P. Expansion and long-term culture of differentiated normal rat urothelial cells in vitro. In Vitro Cell Dev Biol Anim 2001;37:419-29.
43. Ozaki K, Sukata T, Yamamoto S, et al. High susceptibility of p53(+/-) knockout mice in N-butyl-N-(4-hydroxybutyl)nitrosamine urinary bladder carcinogenesis and lack of frequent mutation in residual allele. Cancer Res 1998;58:3806-11.
44. Kumagai Y, Lin LY, Hiratsuka A, et al. Participation of cytochrome P450-2B and -2D isozymes in the demethylenation of methylenedioxymethamphetamine enantiomers by rats. Mol Pharmacol 1994;45:359-65.
45. Bonfanti M, Magagnotti C, Bonati M, Fanelli R, Airoldi L. Pharmacokinetic profile and metabolism of N-nitrosobutyl-(4-hydroxybutyl)amine in rats. Cancer Res 1988;48:3666-9.
46. Moon RC, Kelloff GJ, Detrisac CJ, Steele VE, Thomas CF, Sigman CC. Chemoprevention of OH-BBN-induced bladder cancer in mice by oltipraz, alone and in combination with 4-HPR and DFMO. Anticancer Res 1994;14:5-11.
47. Kang KW, Cho IJ, Lee CH, Kim SG. Essential role of phosphatidylinositol 3-kinase-dependent CCAAT/enhancer binding protein beta activation in the induction of glutathione S-transferase by oltipraz. J Natl Cancer Inst 2003;95:53-66.
48. Nelson CP, Kidd LC, Sauvageot J, et al. Protection against 2-hydroxyamino-1-methyl-6-phenylimidazo[4,5-b]pyridine cytotoxicity and DNA adduct formation in human prostate by glutathione S-transferase P1. Cancer Res 2001;61:103-9.
49. Nelson WG, De Marzo AM, Deweese TL, et al. Preneoplastic prostate lesions: an opportunity for prostate cancer prevention. Ann NY Acad Sci 2001;952:135-44.
50. Strassburg CP, Manns MP, Tukey RH. Differential down-regulation of the UDP-glucuronosyltransferase 1A locus is an early event in human liver and biliary cancer. Cancer Res 1997;57:2979-85.